Extended Data Fig. 1: Extended SU2C-MARK cohort characterization and genomic predictor evaluation. | Nature Genetics

Extended Data Fig. 1: Extended SU2C-MARK cohort characterization and genomic predictor evaluation.

From: Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Extended Data Fig. 1: Extended SU2C-MARK cohort characterization and genomic predictor evaluation.The alternative text for this image may have been generated using AI.

(a) Distributions of clinical characteristics in the Stand Up To Cancer - Mark Foundation (SU2C-MARK) cohort. (b) Best overall response (BOR) distribution by PDL1 tumor proportion score (PDL1 TPS) category (significance assessed by two-sided Fisher’s exact test). CR = Complete Response, PR = Partial Response, SD = Stable Disease, PD = Progressive Disease, NE = Not Evaluable. (c,d) Kaplan-Meier curves for Progression-Free Survival (PFS) in EGFR mutated vs. unmutated patients (c) and KRAS/STK11 comutated patients vs. KRAS mutant STK11 umutated patients (d). Both EGFR mutated patients and KRAS/STK11 comutated patients demonstrated decreased progression-free survival relative to their counterparts (p = 0.03 and p = 0.001, respectively, logrank test).

Back to article page